LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: CD25-T

Solomon, Isabelle / Amann, Maria / Goubier, Anne / Arce Vargas, Frederick / Zervas, Dimitrios / Qing, Chen / Henry, Jake Y / Ghorani, Ehsan / Akarca, Ayse U / Marafioti, Teresa / Śledzińska, Anna / Werner Sunderland, Mariana / Franz Demane, Dafne / Clancy, Joanne Ruth / Georgiou, Andrew / Salimu, Josephine / Merchiers, Pascal / Brown, Mark Adrian / Flury, Reto /
Eckmann, Jan / Murgia, Claudio / Sam, Johannes / Jacobsen, Bjoern / Marrer-Berger, Estelle / Boetsch, Christophe / Belli, Sara / Leibrock, Lea / Benz, Joerg / Koll, Hans / Sutmuller, Roger / Peggs, Karl S / Quezada, Sergio A

Nature cancer

2020  Volume 1, Issue 12, Page(s) 1153–1166

Abstract: Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high affinity receptor subunit for IL-2, is a selective target for Treg depletion ... ...

Abstract Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high affinity receptor subunit for IL-2, is a selective target for Treg depletion in mouse and human malignancies; however, anti-human CD25 antibodies have failed to deliver clinical responses against solid tumors due to bystander IL-2 receptor signaling blockade on effector T cells, which limits their anti-tumor activity. Here we demonstrate potent single-agent activity of anti-CD25 antibodies optimized to deplete Tregs whilst preserving IL-2-STAT5 signaling on effector T cells, and demonstrate synergy with immune checkpoint blockade in vivo. Pre-clinical evaluation of an anti-human CD25 (RG6292) antibody with equivalent features demonstrates, in both non-human primates and humanized mouse models, efficient Treg depletion with no overt immune-related toxicities. Our data supports the clinical development of RG6292 and evaluation of novel combination therapies incorporating non-IL-2 blocking anti-CD25 antibodies in clinical studies.
MeSH term(s) Animals ; Antibodies, Monoclonal/pharmacology ; Interleukin-2/pharmacology ; Mice ; Neoplasms ; Signal Transduction ; T-Lymphocytes, Regulatory
Chemical Substances Antibodies, Monoclonal ; Interleukin-2
Language English
Publishing date 2020-11-09
Publishing country England
Document type Journal Article ; Research Support, Non-U.S. Gov't
ISSN 2662-1347
ISSN (online) 2662-1347
DOI 10.1038/s43018-020-00133-0
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top